Literature DB >> 27699576

Cutaneous localization in multiple myeloma in the context of bortezomib-based treatment: how do myeloma cells escape from the bone marrow to the skin?

Valentina Marchica1, Fabrizio Accardi1,2, Paola Storti1, Cristina Mancini3, Eugenia Martella3, Benedetta Dalla Palma1,2, Marina Bolzoni1, Katia Todoerti4, Magda Marcatti5, Chiara Schifano2, Sabrina Bonomini2, Gabriella Sammarelli2, Antonino Neri6,7, Maurilio Ponzoni5, Franco Aversa1,2, Nicola Giuliani8,9.   

Abstract

The skin is a possible site of extramedullary localization in multiple myeloma (MM) patients; however, the mechanisms involved in this process are poorly understood. We describe the case of a refractory MM patient who developed a cutaneous localization under bortezomib treatment and we further expanded observations in other eight MM patients. We focused on the expression of genes involved in plasma cell skin homing, including CCR10, which was highly expressed. Moreover, we observed a lack of CXCR4 surface expression and the down-regulation of ICAM1/CD54 throughout the progression of the disease, suggesting a possible mechanism driving the escape of MM cells from the bone marrow into the skin.

Entities:  

Keywords:  Bone marrow; Extramedullary disease; Multiple myeloma; Skin homing

Mesh:

Substances:

Year:  2016        PMID: 27699576     DOI: 10.1007/s12185-016-2104-1

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  22 in total

1.  Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)-dependent migration and homing in multiple myeloma.

Authors:  Yazan Alsayed; Hai Ngo; Judith Runnels; Xavier Leleu; Ujjal K Singha; Costas M Pitsillides; Joel A Spencer; Teresa Kimlinger; Joanna M Ghobrial; Xiaoying Jia; Ganwei Lu; Michael Timm; Ashok Kumar; Daniel Côté; Israel Veilleux; Karen E Hedin; G David Roodman; Thomas E Witzig; Andrew L Kung; Teru Hideshima; Kenneth C Anderson; Charles P Lin; Irene M Ghobrial
Journal:  Blood       Date:  2007-04-01       Impact factor: 22.113

Review 2.  Targeting the interplay between myeloma cells and the bone marrow microenvironment in myeloma.

Authors:  Masahiro Abe
Journal:  Int J Hematol       Date:  2011-10-18       Impact factor: 2.490

3.  Plasma cell problems: Case 1. Disseminated cutaneous plasmacytomas treated with total skin electron radiotherapy.

Authors:  Scott R Floyd; Liron Pantanowitz; David F McDermott; Jennifer Yannucci; Jane A Driver; Mary Ann Stevenson; Benjamin D Smith; Lynn D Wilson; Paul G Richardson
Journal:  J Clin Oncol       Date:  2005-05-01       Impact factor: 44.544

4.  Extramedullary disease in multiple myeloma in the era of novel agents.

Authors:  Joan Bladé; Carlos Fernández de Larrea; Laura Rosiñol
Journal:  Br J Haematol       Date:  2015-03-30       Impact factor: 6.998

5.  Development of extramedullary myeloma in the era of novel agents: no evidence of increased risk with lenalidomide-bortezomib combinations.

Authors:  Cindy Varga; Wanling Xie; Jacob Laubach; Irene M Ghobrial; Elizabeth K O'Donnell; Matthew Weinstock; Claudia Paba-Prada; Diane Warren; Michelle E Maglio; Robert Schlossman; Nikhil C Munshi; Noopur Raje; Edie Weller; Kenneth C Anderson; Constantine S Mitsiades; Paul G Richardson
Journal:  Br J Haematol       Date:  2015-06       Impact factor: 6.998

Review 6.  Cutaneous involvement in multiple myeloma: a clinicopathologic, immunohistochemical, and cytogenetic study of 8 cases.

Authors:  Luis Requena; Heinz Kutzner; Gabriele Palmedo; Eduardo Calonje; Celia Requena; Gemma Pérez; María Antonia Pastor; Omar P Sangueza
Journal:  Arch Dermatol       Date:  2003-04

7.  Presence of circulating CCR10+ T cells and elevated serum CTACK/CCL27 in the early stage of mycosis fungoides.

Authors:  Yasuyuki Fujita; Riichiro Abe; Mikako Sasaki; Ayumi Honda; Megumi Furuichi; Yukie Asano; Osamu Norisugi; Tadamichi Shimizu; Hiroshi Shimizu
Journal:  Clin Cancer Res       Date:  2006-05-01       Impact factor: 12.531

8.  Bortezomib overcomes cell-adhesion-mediated drug resistance through downregulation of VLA-4 expression in multiple myeloma.

Authors:  K Noborio-Hatano; J Kikuchi; M Takatoku; R Shimizu; T Wada; M Ueda; M Nobuyoshi; I Oh; K Sato; T Suzuki; K Ozaki; M Mori; T Nagai; K Muroi; Y Kano; Y Furukawa; K Ozawa
Journal:  Oncogene       Date:  2008-10-13       Impact factor: 9.867

9.  Discordant immunophenotypic profiles of adhesion molecules and cytokines in acute myeloid leukemia involving bone marrow and skin.

Authors:  Reena Sachdev; Tracy I George; Erich J Schwartz; Uma N Sundram
Journal:  Am J Clin Pathol       Date:  2012-08       Impact factor: 2.493

10.  Disentangling the microRNA regulatory milieu in multiple myeloma: integrative genomics analysis outlines mixed miRNA-TF circuits and pathway-derived networks modulated in t(4;14) patients.

Authors:  Enrica Calura; Andrea Bisognin; Martina Manzoni; Katia Todoerti; Elisa Taiana; Gabriele Sales; Gareth J Morgan; Giovanni Tonon; Nicola Amodio; Pierfrancesco Tassone; Antonino Neri; Luca Agnelli; Chiara Romualdi; Stefania Bortoluzzi
Journal:  Oncotarget       Date:  2016-01-19
View more
  3 in total

1.  Late-stage myeloma invades kidney without significant effect on renal function: findings from 53 autopsies in a single institute.

Authors:  Junichiro Takano; Sohtaro Mine; Makoto Mochizuki; Noriko Tanaka; Shotaro Hagiwara
Journal:  Int J Hematol       Date:  2018-10-16       Impact factor: 2.490

2.  Cutaneous Involvement in Diseases with Plasma Cell Differentiation: Diagnostic Approach.

Authors:  Magda Zanelli; Andrea Palicelli; Francesca Sanguedolce; Maurizio Zizzo; Alessandra Filosa; Linda Ricci; Camilla Cresta; Giovanni Martino; Alessandra Bisagni; Eleonora Zanetti; Francesco di Donato; Beatrice Melli; Alessandra Soriano; Luca Cimino; Alberto Cavazza; Lisa Francesca Vivian; Stefano Ascani
Journal:  Curr Oncol       Date:  2022-04-24       Impact factor: 3.109

3.  Cutaneous involvement in relapsed multiple myeloma.

Authors:  Valéry Salle; Christophe Attencourt; Marion Chevalier; Lucile Semeria; Xavier Boulu; Jean-Denis Karam; Amar Smail; Jean Schmidt; Pierre Duhaut; Amandine Dernoncourt
Journal:  Clin Case Rep       Date:  2022-09-05
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.